though it is now undergoing a dramatic shift due to high response rates to poly (ADP-ribose) polymerase (PARP) inhibitors inBRCA1/2-deficient cases, allowing them to be added as maintenance to the first line of therapy [7,8]. However, this targeted therapy does not show the same efficacy...